A new investment is pushing artificial intelligence and brain-computer interfaces into one of medicine’s most challenging areas: cancer. OpenAI’s venture capital arm and Peter Thiel’s Founders Fund are investing in Coherence Neuro, a startup building brain implants designed to detect and treat tumors.
The investments form part of a $45 million seed funding round for Coherence. The company is developing AI models that decode electrical signals linked to brain tumors, with the long-term goal of detecting cancer and delivering treatment in real time.
A Brain Implant Designed to Read and Treat Tumors
Coherence has already tested its implant in the brains of three people undergoing tumor removal surgery at the Royal Melbourne Hospital in Australia. The device remained in place for roughly 30 minutes during the safety check, giving the company an early test of its recording capabilities.
The startup is now testing both the recording and stimulation functions in an additional seven patients. Its implant is designed to emit mild electrical stimulation that can halt tumor growth, while its AI models learn to identify signals associated with cancer.
That combination gives Coherence an ambitious target: an implant that can detect cancer signals and provide treatment as those signals appear. The company plans to use the new funding to launch a clinical trial for long-term implantation in patients with glioblastoma.
Coherence also aims to develop implants that treat cancers in other parts of the body. Ben Woodington, the company’s CEO and cofounder, described the work as part of a broader shift linking brain-computer interfaces with AI development.
“There is ‘growing synergy’ between the big AI labs and companies building devices to decode the brain, known as brain-computer interfaces,” Woodington said. He also called AI a “perfect use case” for brain-computer interfaces because the devices generate massive datasets.
Why AI Investors Are Moving Toward Brain Interfaces
Brain implants create a stream of electrical data, and Coherence wants to use that information to train models that can recognize patterns connected to tumors. Woodington said, “The idea of capturing data to train better models and use it to optimize treatments is going to be super important.”
That interest connects Coherence to a wider investment push around brain-computer interfaces. OpenAI announced in January that it was investing in Merge Labs, a company co-founded by Sam Altman, the CEO of OpenAI. Merge Labs came out of stealth with $252 million in initial funding and is pursuing ultrasound technology to decode information from the brain.
OpenAI said it was funding Merge Labs because brain-computer interfaces “will create a natural, human-centered way for anyone to seamlessly interact with AI.” OpenAI also said it would collaborate with Merge Labs on scientific foundation models and frontier tools.
Ian Hathaway said, “We are proud to be backing them on this exciting mission.” Together, these investments show how AI companies and venture capital firms are supporting different approaches to reading brain signals, from ultrasound decoding to implanted electrical sensors.
Investment Without Access to Brain Data
Peter Thiel’s venture capital firm has also backed Neuralink and CTRL-labs. Elon Musk is associated with Neuralink, while Facebook acquired CTRL-labs in 2019. The Founders Fund’s investment in Coherence extends that history into a company focused on cancer detection and treatment.
Coherence has made clear that OpenAI will not have access to its brain or health data. Woodington said, “No hay nada en los contratos ni en los acuerdos que implique que vayamos a compartir algún dato cerebral u otros datos de salud que estemos generando.”
That boundary matters because Coherence’s research depends on sensitive information gathered from patients, including electrical signals from brains undergoing tumor removal surgery. The company’s plans center on using those signals to build models and test stimulation, not on giving OpenAI access to the underlying brain or health data.
The next major step is the planned clinical trial for long-term implantation in people with glioblastoma. Coherence must move from short safety checks and testing in patients during surgery toward an implant that can remain in place and support ongoing detection and treatment.
The company’s $45 million seed round gives it funding to begin that path, while OpenAI’s investment places brain-computer interfaces inside a larger AI strategy. If Coherence’s models can learn the electrical signals connected to tumors, the implant could become both a sensor and a treatment device.
The work now sits at the intersection of venture capital, medical research and AI model development. Coherence is starting with brain tumors, but its stated goal reaches beyond them: implants that can detect and treat cancers in other parts of the body.
Based on
